CBL-514 injection

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cellulite

Conditions

Cellulite

Trial Timeline

May 10, 2023 → Jan 5, 2024

NCT ID

NCT05836779

About CBL-514 injection

CBL-514 injection is a phase 2 stage product being developed by Caliway Biopharmaceuticals for Cellulite. The current trial status is completed. This product is registered under clinical trial identifier NCT05836779. Target conditions include Cellulite.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07140939	Phase 3	Recruiting	Sep 1, 2025	Sep 1, 2026	Subcutaneous Fat
NCT05736107	Phase 2	Completed	May 30, 2023	May 20, 2024	Subcutaneous Fat
NCT05836779	Phase 2	Completed	May 10, 2023	Jan 5, 2024	Cellulite
NCT04897412	Phase 2	Completed	Feb 14, 2022	Mar 22, 2023	Subcutaneous Fat

Competing Products

1 competing product in Cellulite

See all competitors

Product	Company	Stage	Hype Score
40 mg CBL-514 + 60 mg CBL-514 + 80 mg CBL-514	Caliway Biopharmaceuticals	Phase 2	51

Other Products from Caliway Biopharmaceuticals

CBL-514 InjectionPhase 3

CBL-514Phase 2

CBL-514 InjectionPhase 2

10 mg CBL-514 per injection + 15 mg CBL-514 per injectionPhase 2